Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Sheng-rong Wan"'
Autor:
Hui-li Xu, Sheng-rong Wan, Ying An, Qi Wu, Yi-hang Xing, Chen-hao Deng, Ping-ping Zhang, Yang Long, Bu-tuo Xu, Zong-zhe Jiang
Publikováno v:
Cell Death Discovery, Vol 10, Iss 1, Pp 1-16 (2024)
Abstract Nonalcoholic fatty liver disease (NAFLD) is a group of chronic liver disease which ranges from simple steatosis (NAFL) to non-alcoholic steatohepatitis (NASH) and is characterized by lipid accumulation, inflammation activation, fibrosis, and
Externí odkaz:
https://doaj.org/article/f962b924020b4180a7276e9ab46acd76
Autor:
Chen Zeng, Sheng-Rong Wan, Man Guo, Xiao-Zhen Tan, Yan Zeng, Qi Wu, Jia-Jie Xie, Pijun Yan, Yang Long, Lemin Zheng, Zong-Zhe Jiang, Fang-Yuan Teng, Yong Xu
Publikováno v:
Biomedicine & Pharmacotherapy, Vol 177, Iss , Pp 117065- (2024)
Metabolic diseases are a group of disorders caused by metabolic abnormalities, including obesity, diabetes, non-alcoholic fatty liver disease, and more. Increasing research indicates that, beyond inherent metabolic irregularities, the onset and progr
Externí odkaz:
https://doaj.org/article/aa81d985565047ceb0df14d9ec5df15a
Autor:
Ying An, Kang Geng, Hong-ya Wang, Sheng-rong Wan, Xiu-mei Ma, Yang Long, Yong Xu, Zong-zhe Jiang
Publikováno v:
Cell Communication and Signaling, Vol 21, Iss 1, Pp 1-16 (2023)
Abstract Hyperglycaemia-induced endothelial dysfunction is a key factor in the pathogenesis of diabetic microangiopathy and macroangiopathy. STING, which is a newly discovered regulator of innate immunity, has also been reported to play an important
Externí odkaz:
https://doaj.org/article/6d6e9197f0b340139f7aebb43375901c
Publikováno v:
Cardiovascular Diabetology, Vol 22, Iss 1, Pp 1-17 (2023)
Abstract Diabetes mellitus is a metabolic disease characterized by long-term hyperglycaemia, which leads to microangiopathy and macroangiopathy and ultimately increases the mortality of diabetic patients. Endothelial dysfunction, which has been recog
Externí odkaz:
https://doaj.org/article/4bfa6e69082e4a699541366119bccba2
Autor:
Bu-tuo Xu, Fang-yuan Teng, Qi Wu, Sheng-rong Wan, Xin-yue Li, Xiao-zhen Tan, Yong Xu, Zong-zhe Jiang
Publikováno v:
Cell Death Discovery, Vol 8, Iss 1, Pp 1-10 (2022)
Abstract In 2020, a group of experts officially suggested metabolic dysfunction associated with fatty liver disease “MAFLD” as a more appropriate overarching term than NAFLD, indicating the key role of metabolism in fatty liver disease. Bdh1, as
Externí odkaz:
https://doaj.org/article/edec95f6ed83446090e129e0283b6a9b
Autor:
Wei Fan, Sheng-rong Wan, Man Guo, Xiaozhen Tan, Fang-yuan Teng, Zong-zhe Jiang, Chen-lin Gao, Yong Xu, Xin-yue Li, Bu-tuo Xu
Ketogenic diet (KD) and β-Hydroxybutyrate (βOHB) has been widely reported as an effective therapy for metabolic diseases. β-hydroxybutyrate dehydrogenase 1 (Bdh1) is the rate-limiting enzyme of ketone metabolism. In this study, we investigated the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6aeee6140588ec1188a0ccfaf00ccc10
https://doi.org/10.21203/rs.3.rs-976505/v1
https://doi.org/10.21203/rs.3.rs-976505/v1
